Beyond Statins: Transforming LDL-C Management with Early Combination Therapy and CETP Inhibition
Released On
July 17, 2025
Expires On
July 17, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Cardiology, Endocrinology, Primary Care
Topics
Cardiovascular Disease, Heart, Heart Disease
CME INFO
Beyond Statins: Transforming LDL-C Management with Early Combination Therapy and CETP Inhibition
This activity is jointly provided by Global Education Group (GLOBAL) and PLATFORMQ HEALTH EDUCATION, LLC (PQHE), in collaboration with the American Society for Preventive Cardiology (ASPC).
Acknowledgement
This program has been supported by an independent educational grant from NewAmsterdam Pharma.
Date of Release/Expiration
This activity was released on July 17, 2025 and is valid until July 17, 2026. Requests for credit must be made no later than July 17, 2026.
Credit Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
Target Audience
The educational design of this activity addresses the needs of cardiologists, lipidologists, and primary care providers.
Program Overview
Evidence has shown that cumulative prior exposure to elevated LDL-C is a critical driver of ASCVD risk in patients. However, many clinicians need more education on how factors like lifetime cholesterol exposure, lipoprotein(a) [Lp(a)] levels, and coronary artery calcium (CAC) scores should influence the aggressiveness of LDL-C-lowering treatment. Join an expert panel of two cardiologists and one primary care provider to discuss CETP inhibitors and how combining novel therapies with current treatments, including statins and ezetimibe, can enhance patient care. Clinicians will be equipped with practical insights on aggressive LDL-C management, patient-centered treatment strategies, and how emerging therapies can address gaps in current practice.
Educational Objectives
After completing this activity, the participant should be better able to:
- Identify the rationale for new agents to reduce residual LDL-C elevations and other lipoproteins contributing to ASCVD risk in high-risk patients
- Contrast guideline-recommended strategies against current evidence for early combination therapy during treatment intensification in people at high risk for or with ASCVD
- Explain efficacy and safety data from recent clinical trials of a novel CETP inhibitor and other emerging non-statin agents on LDL-C and other lipoprotein levels
Physician Accreditation Statment
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditaiton Support
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Technical Support
For any technical issues or issues with your CME Certificate, please contact MedLive at 877-394-1306 or at [email protected].
Medlive Privacy Privacy Policy
By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”
You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/"